Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR T for Relapsed/Refractory B-cell Malignancies
NCT03559439Phase 1Unknown
- Sponsor
- Shanghai Tongren Hospital
- Start
- Apr 2018
- Primary completion
- Nov 2021
- Countries
- 1
01
Overview
Phase 1, open-label trial of PTA001 in B cell acute lymphoblastic leukemia (B-ALL), B cell lymphoma and B-cell malignancy, sponsored by Shanghai Tongren Hospital. Primary endpoint: Adverse Events at 24 weeks. Status: unknown.
02
Drugs
PTA001
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B cell lymphomaB-cell malignancy
Beyond the preview
Go deeper on NCT03559439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03559439.